In SOD1-G93A mice, intraperitoneal Clemastine significantly increased median survival in the short-treatment group, while the long-treatment group showed no significant difference from vehicle controls. In male Sprague-Dawley rats following bilateral common carotid artery ligation, intraperitoneal Clemastine reversed reduced myelin thickness compared with PBS treatment after ligation. In male APP/PS1 transgenic mice, oral Clemastine reduced cortical Aβ plaque numbers and covering area compared with chow without Clemastine. [1,2,3]
Median survival in SOD1-G93A mice
Animal study · SOD1-G93A mice [1]
Clemastine treatment up to postnatal day 120 prolongs survival in SOD1-G93A mice. When clemastine was instead administrated in SOD1-G93A mice up to the end stage (long treatment, blue line), it failed to affect disease progression and survival.
Conditions shared by the study groups
- Route
- intraperitoneal injection
- Treatment course
- five times a week by intraperitoneal injection starting from postnatal day 40 (a time that provided promising results with a lower dose of 10 mg/kg) until either the end stage or postnatal day 120.
- Vehicle
- 30 % sulfobutylether-β-cyclodextrin (SBE)
- Clemastine 50 mg/kg body weight
- Model: SOD1-G93A mice
Methods and source locations
Compound reported in the paper: Clemastine
The paper names Clemastine without stating the salt or form; not verified as the fumarate form supplied as A10226. No dose conversion or lot validation.
Methods > Pharmacological treatments with clemastine and analysis of disease progression (S14, S15); Results > Clemastine short treatment prolongs survival in SOD1-G93A mice (S58, S60, S61)
median survival: median survival; comparator: Vehicle groups received 30 % SBE. — Results > Clemastine short treatment prolongs survival in SOD1-G93A mice (S60, S61)
Clemastine 50 mg/kg body weight · Methods > Pharmacological treatments with clemastine and analysis of disease progression (S14); Results > Clemastine short treatment prolongs survival in SOD1-G93A mice (S60, S61)
Clemastine and myelin thickness after BCCAO
Animal study · male Sprague-Dawley (SD) rats; bilateral common carotid artery ligation (BCCAO) [2]
Male Sprague-Dawley rats received intraperitoneal Clemastine at 1mg/kg after bilateral common carotid artery ligation, with PBS-treated rats as controls. Clemastine reversed the reduced myelin thickness in BCCAO rats, with an averaged g-ratio of 0.7.
Conditions shared by the study groups
- Route
- intraperitoneally injected
- Treatment course
- after BCCAO; at 28 days
- Clemastine 1mg/kg
- Model: male Sprague-Dawley (SD) rats; bilateral common carotid artery ligation (BCCAO)
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Clemastine
The paper names Clemastine without stating the salt or form; not verified as the fumarate form supplied as A10226. No dose conversion or lot validation.
Methods > Animals (S1, S3, S4, S5); Methods > Treatment of microglial cells culture (S26); Methods > Treatment of OPCs culture (S43); Methods > Electron microscopy (S113); Results > Ultrastructural study (S184, S187)
axon diameter/fiber diameter of myelinated axons: axon diameter/fiber diameter of myelinated axons; comparator: intraperitoneally injected with the same volume of 0.01 mol/L (M) phosphate-buffer saline (PBS) buffer after BCCAO — Results > Ultrastructural study (S184, S187)
Clemastine 1mg/kg · Methods > Animals (S4); Methods > Electron microscopy (S113); Results > Ultrastructural study (S187)
Clemastine and cortical amyloid plaques in APP/PS1 mice
Animal study · Male APP/PS1 transgenic mice; cortex; n = 4 mice per group [3]
Male APP/PS1 transgenic mice received oral Clemastine at 10 mg/kg/day, with chow without clemastine as the control. Cortical Aβ plaque numbers and covering area showed an average reduction of over 50%.
Conditions shared by the study groups
- Route
- orally administrated
- Treatment course
- 15-month-old APP/PS1 mice for 2 months
- Vehicle
- standard laboratory chow
- Clemastine 10 mg/kg/day
- Model: Male APP/PS1 transgenic mice; cortex; n = 4 mice per group
Methods and source locations
Compound reported in the paper: Clemastine
Evidence for Clemastine as the sodium form reported in the paper, not the fumarate form supplied as A10226; no salt equivalence, dose conversion or lot validation.
Materials and Methods > Animals (S2); Materials and Methods > Drug Treatments (S4, S5); Results > Chronic Treatment of Clemastine Rescues the Short-Term Memory Deficit of Aged APP/PS1 Mice (S60); Results > Chronic Treatment of Clemastine Ameliorates the Accumulation of Amyloid-β in the Aged APP/PS1 Mice Brain (S74, S75); FIGURE 2 legend (S120, S123)
covering areas of Aβ plaques: covering areas of Aβ plaques; comparator: the same chow without clemastine — Results > Chronic Treatment of Clemastine Ameliorates the Accumulation of Amyloid-β in the Aged APP/PS1 Mice Brain (S74, S75)
Clemastine 10 mg/kg/day · Materials and Methods > Drug Treatments (S4); Results > Chronic Treatment of Clemastine Rescues the Short-Term Memory Deficit of Aged APP/PS1 Mice (S60); Results > Chronic Treatment of Clemastine Ameliorates the Accumulation of Amyloid-β in the Aged APP/PS1 Mice Brain (S75)